EUVIMEDEUVIMED entdecken
Crossref

Combined in silico strategy for repurposing DrugBank entries towards introducing potential anti-SARS-CoV-2 drugs

Ghazaleh Ghavami, Setare Adibzadeh, Shahin Amiri, Soroush Sardari iD

Canadian Journal of Physiology and Pharmacology · 2023

DOI: 10.1139/cjpp-2022-0309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2023. Verfasst von Ghazaleh Ghavami und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: Drug Repositioning, COVID-19 Drug Treatment, Databases, Pharmaceutical, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from China in December 2019 led to the coronavirus disorder 2019 pandemic, which has affected tens of millions of humans worldwide. Various in silico research via bio-cheminformatics methods were performed to examine the efficiency of a range of repurposed approved drugs with a new role as anti-SARS-CoV-2 drugs. The current study has been performed to screen the approved drugs in the DrugBank database based on a novel bioinformatics/cheminformatics strategy to repurpose available approved drugs towards introducing them as a possible anti-SARS-CoV-2 drug. As a result, 96 approved drugs with the best docking scores passed through several relevant filters were presented as the candidate drugs with potential novel antiviral activities against the SARS-CoV-2 virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningCOVID-19 Drug TreatmentDatabases, PharmaceuticalSARS-CoV-2HumansDrug Evaluation, PreclinicalLigandsDrug DesignMolecular Docking SimulationViral Nonstructural ProteinsProtein Conformation

Stichwörter der Autor:innen

DrugBankSARS-CoV-2dockingdrug repurposingin silico screening

Substanzen

LigandsViral Nonstructural Proteins

Autor:innen und Institutionen

  • Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

ORCID-Profile: Soroush Sardari

Zitieren

APA

Ghavami, G., Adibzadeh, S., Amiri, S., & Sardari, S. (2023). Combined in silico strategy for repurposing DrugBank entries towards introducing potential anti-SARS-CoV-2 drugs. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2022-0309

Vancouver

Ghavami G, Adibzadeh S, Amiri S, Sardari S. Combined in silico strategy for repurposing DrugBank entries towards introducing potential anti-SARS-CoV-2 drugs. Canadian Journal of Physiology and Pharmacology. 2023. doi:10.1139/cjpp-2022-0309

BibTeX
@article{Ghavami2023,
  author = {Ghavami, Ghazaleh and Adibzadeh, Setare and Amiri, Shahin and Sardari, Soroush},
  title = {Combined in silico strategy for repurposing DrugBank entries towards introducing potential anti-SARS-CoV-2 drugs},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2023},
  doi = {10.1139/cjpp-2022-0309}
}
Kostenlos starten →